Histogen, Inc.
Human extracellular matrix (hECM) combined with antimicrobial peptides (AMP) for infected wound treatment and tissue regeneration
- Sector
- Medtech
- Headquarters
- San Diego, CA
- Latest Form D
- $5M, Jul 2022
- Total capital
- $37.5M
- Federal grants
- $1M
- 2 awards · 2015–2017
- Rank in peer group#26 of 27
- Private capital raised
- $36.5M
- 5 Form D · last Jul 2022
- 51 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 14 pending · first 2016
- Rank in peer group#2 of 27
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$5M
- Private capital raisedForm D · SEC · 4th filing$189K
- Federal grantNSF · Phase II · STTR Phase II: A novel wound dressing for infection control and tissue regeneration$750K
- Federal grantNSF · Phase I · STTR Phase I: A novel wound dressing for infection control and tissue regeneration$270K
- Private capital raisedForm D · SEC · 3rd filing$1M
- Private capital raisedForm D · SEC · 2nd filing$25.3M
- Private capital raisedForm D · SEC · 1st filing$5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 27 peers
Line = medianMedtech · Material
- Federal grantsBelow median
- Granted patents#2 · top 7%
- Linked publications#1 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Gail NaughtonResearcherExecutive OfficerLinked by 5 patents · $270K in grants as PI
- Brian L. SatzDirectorNamed in SEC Form D filings
- Brian W. Satz, Esq.DirectorNamed in SEC Form D filings
- Daniel L. KisnerDirectorNamed in SEC Form D filings
- Daniel W. Kisner, M.D.DirectorNamed in SEC Form D filings
- David H. CreanDirectorNamed in SEC Form D filings
Show all 21 people
- David W. Crean, Ph.D.DirectorNamed in SEC Form D filings
- Hayden Yizhuo ZhangDirectorNamed in SEC Form D filings
- Jonathan JacksonDirectorNamed in SEC Form D filings
- Joyce J. ReyesExecutive OfficerNamed in SEC Form D filings
- Martin A. LatterichExecutive OfficerNamed in SEC Form D filings
- Moya A. DanielsExecutive OfficerNamed in SEC Form D filings
- Richard PascoeExecutive Officer, DirectorNamed in SEC Form D filings
- Rochelle L. FuhrmannDirectorNamed in SEC Form D filings
- Stephen ChangDirectorNamed in SEC Form D filings
- Stephen W. Chang, Ph.D.DirectorNamed in SEC Form D filings
- Steven J. MentoExecutive Officer, DirectorNamed in SEC Form D filings
- Steven W. Mento, Ph.D.DirectorNamed in SEC Form D filings
- Susan A. KnudsonExecutive OfficerNamed in SEC Form D filings
- Susan L. Windham-BannisterDirectorNamed in SEC Form D filings
- Yizhuo ZhangDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 21- GrantedCaspase Inhibitors And Methods Of Use ThereofUSPTOUS 11,597,703
- Granted(S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC Acid Derivatives And Related Compounds As Caspase Inhibitors For Treating Cardiovascular DiseasesUSPTOUS 11,447,497
- PendingConditioned Medium And Extracellular Matrix Compositions From Cells Cultured Under Hypoxic ConditionsUSPTOApplication 17694588
Show all 21 patent records
- Caspase Inhibitors And Methods Of Use ThereofMar 7, 2023 · US 11,597,703Granted
- (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC Acid Derivatives And Related Compounds As Caspase Inhibitors For Treating Cardiovascular DiseasesSep 20, 2022 · US 11,447,497Granted
- Conditioned Medium And Extracellular Matrix Compositions From Cells Cultured Under Hypoxic ConditionsJun 30, 2022 · Application 17694588Pending
- Conditioned Medium And Extracellular Matrix Compositions From Cells Cultured Under Hypoxic ConditionsMar 15, 2022 · US 11,274,276Granted
- Conditioned Medium And Extracellular Matrix Compositions From Cells Cultured Under Hypoxic ConditionsJan 21, 2020 · US 10,538,736Granted
- Extracellular Matrix Compositions For The Treatment Of CancerDec 4, 2018 · US 10,143,708Granted
- Conditioned Medium and Extracellular Matrix Compositions from Cells Cultured under Hypoxic Conditions for Methods of Treating Tissue InjuryDec 6, 2016 · US 9,512,403Granted
- Extracellular Matrix Compositions For The Treatment Of CancerNov 29, 2016 · US 9,506,038Granted
- Conditioned Medium And Extracellular Matrix Compositions And Uses ThereofApplication 62713984Pending
- Extracellular Vesicles Derived From Cells Cultured Under Hypoxic Conditions And Uses ThereofApplication 62623851Pending
- Extracellular Matirix Compositions For The Treatment Of Cancer Or Immunological DiseasesApplication PCTUS2016030204Pending
- Conditioned Medium And Extracellular Matrix Compositions From Cells Cultured Under Hypoxic ConditionsApplication PCTUS2010041583Pending
- Extracellular Matrix CompositionsApplication PCTUS2009032697Pending
- Extracellular Matrix Compositions For The Treatment Of CancerApplication PCTUS2009032677Pending
- Compositions And Methods For Reducing InflammationApplication 63060560Pending
- Conditioned Medium And Methods Of Use ThereofApplication PCTUS2020030828Pending
- Conditioned Medium And Extracellular Matrix Compositions And Uses ThereofApplication PCTUS2019044405Pending
- Novel Caspase InhibitorsApplication PCTUS2019039702Pending
- Conditioned Medium And Methods Of Use ThereofApplication 62842245Pending
- Extracellular Vesicles Derived From Cells Cultured Under Hypoxic Conditions And Uses ThereofApplication PCTUS2019015855Pending
- Nutraceutical Products From Cell Conditioned Medium From Cells Cultured Under Hypoxic ConditionsApplication PCTUS2019013307Pending
Recent research by its founders
- Regenerative Skincare Technologies Derived From Human Fibroblasts: Growth Factors and Exosomes for Transformative Outcomes20249 cites
- Fibroblast‐derived growth factors and exosomes as cosmeceuticals202310 cites
- Targeting Multiple Hallmarks of Skin Aging: Preclinical and Clinical Efficacy of a Novel Growth Factor-Based Skin Care Serum202217 cites
Related companies, and why
- Vibronix, Inc.Similar federal contract value in Medtech · null in contracts
- Kepler Diagnostics Inc.Similar federal contract value in Medtech · null in contracts
- CORAVIE MEDICAL, INC.Similar federal contract value in Medtech · null in contracts
- SynchNeuroSimilar federal contract value in Medtech · null in contracts
- NONAGEN BIOSCIENCE CORPORATIONSimilar federal contract value in Medtech · null in contracts
- IHEALTHSCREEN, INC.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .